药学学报, 2017, 52(7): 1019-1026
引用本文:
柏兆方, 高源, 左晓彬, 王伽伯, 肖小河. 免疫调控与特异质型药物性肝损伤发生机制研究进展[J]. 药学学报, 2017, 52(7): 1019-1026.
BAI Zhao-fang, GAO Yuan, ZUO Xiao-bin, WANGJia-bo, XIAO Xiao-he. Progress in research on the pathogenesis of immune regulation and idiosyncratic drug-induced liver injury[J]. Acta Pharmaceutica Sinica, 2017, 52(7): 1019-1026.

免疫调控与特异质型药物性肝损伤发生机制研究进展
柏兆方1, 高源1,2, 左晓彬1, 王伽伯1, 肖小河3
1. 解放军302医院全军中医药研究所, 北京 100039;
2. 北京中医药大学中药学院, 北京 100029;
3. 解放军302医院中西医结合诊疗与研究中心, 北京 100039
摘要:
特异质型药物性肝损伤(idiosyncratic drug-induced liver injury,IDILI)是仅在少数人群发生的药物不良反应,其发生往往与服药时间、剂量无明确对应关系,具有不可预测性和发病率低等特点。研究表明,IDILI是机体、环境和药物因素协同作用的结果,而机体免疫是IDILI发生的主要诱因。目前,化学药物诱导的IDILI研究较为广泛和深入,形成了多种免疫学机制假说,较好地阐释了其发病特点和机制。近年来,中药特异质肝损伤也逐步被证实,并且形成了中药特异质肝损伤免疫应激“三因致毒”机制假说,较为全面地揭示了中药IDILI的发病特点和机制。本文就化学药物和中药诱导的IDILI免疫学机制假说进行综述,以期为IDILI评价和临床风险防控对策建立提供科学依据。
关键词:    特异质型药物性肝损伤      免疫调控      化学药物      中药      机制假说     
Progress in research on the pathogenesis of immune regulation and idiosyncratic drug-induced liver injury
BAI Zhao-fang1, GAO Yuan1,2, ZUO Xiao-bin1, WANGJia-bo1, XIAO Xiao-he3
1. China Military Institute of Chinese Materia, 302 Military Hospital, Beijing 100039, China;
2. School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China;
3. Integrative Medical Center, 302 Military Hospital, Beijing 100039, China
Abstract:
Idiosyncratic drug-induced liver injury(IDILI)is an adverse drug reaction that occurs only in a minority of the population. IDILI also has many characteristics such as unpredictable and low morbidity, its occurrence has often not been clearly correlated with the dose, route, or duration of drug administration. Several studies have shown that IDILI is a synergistic effect which was caused by body diathesis, environment and drugs. In addition, evidence also suggests that most IDILIs are mediated by immunity. Chemical medicines-related IDILIs have been extensively studied, and a variety of immunological mechanism hypotheses have also emerged to explain the pathogenesis and characteristics of chemical medicines-related IDILIs. However, the traditional Chinese medicine(TCM)-related IDILI has always been neglected due to the complexity and specificity of TCM. In recent years, TCM-related IDILI has been gradually confirmed by researchers, and formed a new hypothesis, a immunological stress-mediated tri-elements synergetic mechanism hypothesis, which can reveal the pathogenesis and clinical characteristics of TCM-related IDILI. This paper is prepared to summarize the immunological mechanism hypotheses of chemical medicine-related IDILI and TCM-related IDILI to provide a scientific basis for guiding IDILI research and establishing its clinical risk prevention and control measures.
Key words:    idiosyncratic drug-induced liver injury    immune regulation    chemical medicine    traditional Chinese medicine    mechanism hypothesis   
收稿日期: 2017-04-05
DOI: 10.16438/j.0513-4870.2017-0315
基金项目: 国家自然科学基金青年基金资助项目(81503350);国家自然科学基金重点资助项目(81630100);国家“重大新药创制”科技重大专项课题(2015ZX09501-004-001-008);国家公益性行业科研专项课题(201507004-04)
通讯作者: 柏兆方,Tel:86-10-66933325,E-mail:baizf2008@126.com;肖小河,Tel:86-10-66933322,E-mail:pharmacy302@126.com
Email: baizf2008@126.com;pharmacy302@126.com
相关功能
PDF(303KB) Free
打印本文
0
作者相关文章
柏兆方  在本刊中的所有文章
高源  在本刊中的所有文章
左晓彬  在本刊中的所有文章
王伽伯  在本刊中的所有文章
肖小河  在本刊中的所有文章

参考文献:
[1] Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview [J]. Exp Opin Drug Safety, 2007, 6: 673-684.
[2] Medina-Caliz I, Robles-Diaz M, Garcia-Munoz B, et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury [J]. J Hepatol, 2016, 65: 532-542.
[3] Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives [J]. Gastroenterology, 2014, 146: 914-928.
[4] Cho TE, Uetrecht J. How reactive metabolites induce an immune response that sometimes leads to an idiosyncratic drug reaction [J]. Chem Res Toxicol, 2017, 30: 295-314.
[5] Dara L, Liu ZX, Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications [J]. Liver Int, 2016, 36: 158-165.
[6] Thompson RA, Isin EM, Ogese MO, et al. Reactive metabo­lites: current and emerging risk and hazard assessments [J]. Chem Res Toxicol, 2016, 29: 505-533.
[7] Uetrecht J, Naisbitt DJ. Idiosyncratic adverse drug reactions: current concepts [J]. Pharmacol Rev, 2013, 65: 779-808.
[8] Chipinda I, Hettick JM, Siegel PD. Haptenation: chemical reactivity and protein binding [J]. J Allergy(Cairo), 2011, 2011: 839682.
[9] Uetrecht J. Idiosyncratic drug reactions: past, present, and future [J]. Chem Res Toxicol, 2008, 21: 84-92.
[10] Satoh H, Martin BM, Schulick AH, et al. Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroace­tylated carboxylesterase [J]. Proc Natl Acad Sci U S A, 1989, 86: 322-326.
[11] Roth RA, Ganey PE. Animal models of idiosyncratic drug-induced liver injury-current status [J]. Crit Rev Toxicol, 2011, 41: 723-739.
[12] Aithal GP, Ramsay L, Daly AK, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity [J]. Hepatology, 2004, 39: 1430-1440.
[13] Jenkins RE, Meng X, Elliott VL, et al. Characterisation of flucloxacillin and 5-hydroxymethyl flucloxacillin haptenated HAS in vitro and in vivo [J]. Proteomics Clin Appl, 2009, 3: 720-729.
[14] Callan HE, Jenkins RE, Maggs JL, et al. Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation [J]. Chem Res Toxicol, 2009, 22: 937-948.
[15] Elghaiesh S, Monshi MM, Whitaker P, et al. Characterization of the antigen specificity of T-cell clones from piperacillin-hypersensitive patients with cystic fibrosis [J]. J Pharmacol Exp Ther, 2012, 341: 597-610.
[16] Monshi MM, Faulkner L, Gibson A, et al. Human leukocyte antigen(HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury [J]. Hepatology, 2013, 57: 727-739.
[17] Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir [J]. Lancet, 2002, 359: 727-732.
[18] Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin [J]. Nat Genet, 2009, 41: 816-819.
[19] Kaniwa N, Saito Y. Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury [J]. Pharma­cogenomics, 2013, 14: 595-598.
[20] Hirata K, Takagi H, Yamamoto M, et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study [J]. Pharmacogenomics J, 2008, 8: 29-33.
[21] Spraggs CF, Budde LR, Briley LP, et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer [J]. J Clin Oncol, 2011, 29: 667-673.
[22] Hautekeete ML, Horsmans Y, Waeyenberge CV, et al. HLA association of amoxicillin-clavulanate-induced hepatitis [J]. Gastroenterology, 1999, 117: 1181-1186.
[23] Daly AK, Aithal GP, Leathart JB, et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes [J]. Gastroenterology, 2007, 132: 272-281.
[24] Aithal GP, Day CP, Leathart JB, et al. Relationship of poly­morphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis [J]. Pharmacogenetics, 2000, 10: 511-518.
[25] Vuilleumier N, Rossier MF, Chiappe A, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis [J]. Eur J Clin Pharmacol, 2006, 62: 423-429.
[26] Huang YS, Su WJ, Huang YH, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinine oxi­doreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury [J]. J Hepatol, 2007, 47: 128-134.
[27] Watanabe I, Tomita A, Shimizu M, et al. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus [J]. Clin Pharmacol Ther, 2003, 73: 435-455.
[28] Matzinger P. Tolerance, danger, and the extended family [J]. Immunology, 1994, 12: 991-1045.
[29] Janeway CA. Presidential Address to The American Association of Immunologists. The road less traveled by: the role of innate immunity in the adaptive immune response [J]. J Immunol, 1998, 161: 4629-4636.
[30] Pichler WJ. The p-i concept: pharmacological interaction of drugs with immune receptors [J]. World Allergy Organ J, 2008, 1: 96-102.
[31] Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetics investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis [J]. Pharmacogenomics J, 2008, 8: 186-195.
[32] Maria VA, Victorino RM. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury [J]. Gut, 1997, 41: 534-540.
[33] Metushi IG, Uetrecht J, Phillips E. Mechanism of isoniazid-induced hepatotoxicity: then and now [J]. Br J Clin Pharmacol, 2016, 81: 1030-1036.
[34] Wuillemin N, Adam J, Fontana S, et al. HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin [J]. J Immunol, 2013, 190: 4956-4964.
[35] Yaseen FS, Saide K, Kim SH, et al. Promiscuous T-cell responses to drugs and drug-haptens [J]. J Allergy Clin Immunol, 2015, 136: 474-6.e8.
[36] Metushi IG, Hayes MA, Uetrecht J. Treatment of PD-1-/- mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients [J]. Hepatology, 2015, 61: 1332-1342.
[37] Mak A, Uetrecht J. The role of CD8 T cells in amodiaquine-induced liver injury in PD1-/- mice cotreated with anti-CTLA-4 [J]. Chem Res Toxicol, 2015, 28: 1567-1573.
[38] Chakraborty M, Fullerton AM, Semple K, et al. Drug-induced allergic hepatitis develops in mice when myeloid-derived suppressor cells are depleted prior to halothane treatment [J]. Hepatology, 2015, 62: 546-557.
[39] Tobon GJ, Canas C, Jaller JJ, et al. Serious liver disease induced by infliximab [J]. Clin Rheumatol, 2007, 26: 578-581.
[40] Yun J, Cai F, Lee FJ, et al. T-cell-mediated drug hypersensi­tivity: immune mechanisms and their clinical relevance [J]. Asia Pac Allergy, 2016, 6: 77-89.
[41] Chessman D, Kostenko L, Lethborg T, et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity [J]. Immunity, 2008, 28: 822-832.
[42] Wu Y, Sanderson JP, Farrell J, et al. Activation of T cells by carbamazepine and carbamazepine metabolites [J]. J Allergy Clin Immunol, 2006, 118: 233-241.
[43] Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir [J]. N Engl J Med, 2008, 358: 568-579.
[44] Ostrov DA. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire [J]. Proc Natl Acad Sci U S A, 2012, 109: 9959-9964.
[45] Luyendyk JP, Maddox JF, Cosma GN, et al. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats [J]. J Pharmacol Exp Ther, 2003, 307: 9-16.
[46] Roth RA, Ganey PE. Intrinsic versus idiosyncratic drug-induced hepatotoxicity--two villains or one? [J]. J Pharmacol Exp Ther, 2010, 332: 692-697.
[47] Deng X, Stachlewitz RF, Liguori MJ, et al. Modest inflam­mation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation [J]. J Pharmacol Exp Ther, 2007, 319: 1191-1199.
[48] Buchweitz JP, Ganey PE, Bursian SJ, et al. Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy? [J]. J Pharmacol Exp Ther, 2002, 300: 460-467.
[49] Shaw PJ, Hopfensperger MJ, Ganey PE, et al. Lipopolysac­charide and trovafloxacin coexposure in mice causes idiosyn­crasy-like liver injury dependent on tumor necrosis factor-alpha [J]. Toxicol Sci, 2007, 100: 259-266.
[50] Dugan CM, Macdonald AE, Roth RA, et al. A mouse model of severe halothane hepatitis based on human risk factors [J]. J Pharmacol Exp Ther, 2010, 333: 364-372.
[51] Shaw PJ, Fullerton AM, Scott MA, et al. The role of the hemostatic system in murine liver injury induced by coexposure to lipopolysaccharide and trovafloxacin, a drug with idiosyn­cratic liability [J]. Toxicol Appl Pharmacol, 2009, 236: 293-300.
[52] Cheng L, You Q, Yin H, et al. Effect of polyI:C cotreatment on halothane-induced liver injury in mice [J]. Hepatology, 2009, 49: 215-226.
[53] Wang JB, Ma Z, Niu M, et al. Evidence chain-based causality identification in herb-induced liver injury: exemplification of a well-known liver-restorative herb Polygonum multiflorum [J]. Front Med, 2015, 9: 457-467.
[54] Wang JB, Chunyu LI, Zhu Y, et al. Integrated evidence chain-based identification of Chinese herbal medicine-induced hepatotoxicity and rational usage: exemplification by Poly­gonum multiflorum(He shou wu) [J]. Chin Sci Bull(科学通报), 2016, 61: 971-980.
[55] Zhu Y, Niu M, Chen J, et al. Comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients [J]. J Gastroenterol Hepatol, 2016, 31: 1476-1482.
[56] Zhu Y, Liu SH, Wang JB, et al. Clinical analysis of drug-induced liver injury caused by Polygonum multiflorum and its preparations [J]. Chin J Integr Tradit Chin West Med(中国中西医结合杂志), 2015, 35: 1442-1447.
[57] Li CY, Li XF, Tu C, et al. The idiosyncratic hepatotoxicity of Polygonum multiflorum based on endotoxin model [J]. Acta Pharm Sin(药学学报), 2015, 50: 28-33.
[58] Meng YK, Li CY, Li RY, et al. Mechanism of Polygonum multiflorum-induced liver injury: cis-stilbene glucoside induces immunological idiosyncratic hepatotoxicity by suppressing PPAR-γ in a lipopolysaccharide model [J]. Acta Pharmacol Sin, 2017. DOI: 10.1038/aps.2017.32.
[59] Li CY, Niu M, Bai ZF, et al. Screening for main components associated with the idiosyncratic hepatotoxicity of a tonic herb, Polygonum multiflorum [J]. Front Med, 2017. DOI: 10.1007/s11684-017-0508-9.
[60] He LZ, Yin P, Meng YK, et al. Immunological synergistic mechanisms of trans-/cis-stilbene glycosides in Heshouwu-related idiosyncratic liver injury [J]. Sci Bull, 2017. DOI: 10.1016/j.scib.2017.04.020.
[61] Goda K, Takahashi T, Kobayashi A, et al. Usefulness of in vitro combination assays of mitochondrial dysfunction and apoptosis for the estimation of potential risk of idiosyncratic drug induced liver injury [J]. J Toxicol Sci, 2016, 41: 605-615.
[62] He TT, Gong M, BaiYF, et al. Clinical analysis of two diagnosis methods for herb-induced liver injury [J]. China J Chin Mater Med(中国中药杂志), 2016, 41: 3096-3099.
相关文献:
1.柏兆方, 高源, 左晓彬, 王伽伯, 肖小河.免疫调控与特异质型药物性肝损伤发生机制研究进展[J]. 药学学报,